Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.

≈